A Differential Profile of Biomarkers between Patients with Atrial Fibrillation and Healthy Controls
Abstract
:1. Introduction
2. Materials and Methods
2.1. Design and Population
2.2. Statistical Analysis
3. Results
3.1. Clinical Differences between Cases and Controls
3.2. Analytical Differences between Cases and Controls
3.3. ROC Test
3.4. Multivariate Analysis
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Staerk, L.; Preis, S.R.; Lin, H.; Lubitz, S.A.; Ellinor, P.T.; Levy, D.; Benjamin, E.J.; Trinquart, L. Protein Biomarkers and Risk of Atrial Fibrillation: The FHS. Circ. Arrhythm. Electrophysiol. 2020, 13, e007607. [Google Scholar] [CrossRef] [PubMed]
- Gottdiener, J.S.; Seliger, S.; de Filippi, C.; Christenson, R.; Baldridge, A.S.; Kizer, J.R.; Psaty, B.M.; Shah, S.J. Relation of Biomarkers of Cardiac Injury, Stress, and Fibrosis with Cardiac Mechanics in Patients ≥ 65 Years of Age. Am. J. Cardiol. 2020, 136, 156–163. [Google Scholar] [CrossRef] [PubMed]
- Kwon, C.H.; Kang, J.G.; Lee, H.J.; Kim, N.H.; Sung, J.-W.; Cheong, E.; Sung, K.-C. C-Reactive Protein and Risk of Atrial Fibrillation in East Asians. EP Eur. 2017, 19, 1643–1649. [Google Scholar] [CrossRef] [PubMed]
- Canpolat, U.; Aytemir, K.; Yorgun, H.; Şahiner, L.; Kaya, E.B.; Çay, S.; Topaloğlu, S.; Aras, D.; Oto, A. Usefulness of Serum Uric Acid Level to Predict Atrial Fibrillation Recurrence after Cryoballoon-Based Catheter Ablation. EP Eur. 2014, 16, 1731–1737. [Google Scholar] [CrossRef]
- O’Neal, W.T.; Venkatesh, S.; Broughton, S.T.; Griffin, W.F.; Soliman, E.Z. Biomarkers and the prediction of atrial fibrillation: State of the art. Vasc. Health Risk Manag. 2016, 12, 297–303. [Google Scholar] [CrossRef]
- Boriani, G.; Valenti, A.C.; Vitolo, M. Biomarkers in atrial fibrillation: A constant search for simplicity, practicality, and cost-effectiveness. Kardiol. Pol. 2021, 79, 243–245. [Google Scholar] [CrossRef]
- Gullón, P.; Díez, J.; Cainzos-Achirica, M.; Franco, M.; Bilal, U. Social inequities in cardiovascular risk factors in women and men by autonomous regions in Spain. Gac. Sanit. 2021, 35, 326–332. [Google Scholar] [CrossRef]
- Dudink, E.A.; Weijs, B.; Tull, S.; Luermans, J.G.; Fabritz, L.; Chua, W.; Rienstra, M.; Gelder, I.C.V.; Schotten, U.; Kirchhof, P.; et al. The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation. J. Atr. Fibrillation 2018, 11, 2058. [Google Scholar] [CrossRef]
- Wang, T.J.; Larson, M.G.; Levy, D.; Benjamin, E.J.; Leip, E.P.; Omland, T.; Wolf, P.A.; Vasan, R.S. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 2004, 350, 655–663. [Google Scholar] [CrossRef]
- Stanciu, A.E.; Vatasescu, R.G.; Stanciu, M.M.; Serdarevic, N.; Dorobantu, M. The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. Cytokine 2018, 103, 63–68. [Google Scholar] [CrossRef]
- Palà, E.; Bustamante, A.; Clúa-Espuny, J.L.; Acosta, J.; Gonzalez-Loyola, F.; Ballesta-Ors, J.; Gill, N.; Caballero, A.; Pagola, J.; Pedrote, A.; et al. N-Terminal Pro B-Type Natriuretic Peptide’s Usefulness for Paroxysmal Atrial Fibrillation Detection among Populations Carrying Cardiovascular Risk Factors. Front. Neurol. 2019, 10, 1226. [Google Scholar] [CrossRef] [PubMed]
- Merino-Merino, A.; Saez-Maleta, R.; Salgado-Aranda, R.; AlKassam-Martinez, D.; Pascual-Tejerina, V.; Martin-González, J.; Garcia-Fernandez, J.; Perez-Rivera, J.-A. When should we measure biomarkers in patients with atrial fibrillation to predict recurrences? Am. J. Emerg. Med. 2021, 39, 248–249. [Google Scholar] [CrossRef] [PubMed]
- Ma, X.; Yuan, H.; Luan, H.-X.; Shi, Y.-L.; Zeng, X.-L.; Wang, Y. Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation. Clin. Chim. Acta 2018, 480, 138–142. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.; Qu, X.; Gao, Z.; Zheng, G.; Wang, Y.; Chen, X.; Li, H.; Huang, W.; Zhou, H. Soluble ST2 in Patients with Nonvalvular Atrial Fibrillation and Prediction of Heart Failure. Int. Heart J. 2018, 59, 58–63. [Google Scholar] [CrossRef]
- Chang, K.-W.; Hsu, J.C.; Toomu, A.; Fox, S.; Maisel, A.S. Clinical Applications of Biomarkers in Atrial Fibrillation. Am. J. Med. 2017, 130, 1351–1357. [Google Scholar] [CrossRef]
- Merino-Merino, A.; Gonzalez-Bernal, J.; Fernandez-Zoppino, D.; Saez-Maleta, R.; Perez-Rivera, J.-A. The Role of Galectin-3 and ST2 in Cardiology: A Short Review. Biomolecules 2021, 11, 1167. [Google Scholar] [CrossRef]
- Filion, K.B.; Agarwal, S.K.; Ballantyne, C.M.; Eberg, M.; Hoogeveen, R.C.; Huxley, R.R.; Loehr, L.R.; Nambi, V.; Soliman, E.Z.; Alonso, A. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am. Heart J. 2015, 169, 31–38.e3. [Google Scholar] [CrossRef]
- Bai, Y.; Guo, S.-D.; Liu, Y.; Ma, C.-S.; Lip, G.Y.H. Relationship of troponin to incident atrial fibrillation occurrence, recurrence after radiofrequency ablation and prognosis: A systematic review, meta-analysis and meta-regression. Biomarkers 2018, 23, 512–517. [Google Scholar] [CrossRef]
- Janus, S.E.; Hajjari, J.; Al-Kindi, S. High-sensitivity troponin and the risk of atrial fibrillation in chronic kidney disease: Results from the Chronic Renal Insufficiency Cohort Study. Heart Rhythm 2020, 17, 190–194. [Google Scholar] [CrossRef]
- Kornej, J.; Zeynalova, S.; Büttner, P.; Burkhardt, R.; Bae, Y.J.; Willenberg, A.; Baber, R.; Thaler, A.; Hindricks, G.; Loeffler, M.; et al. Differentiation of atrial fibrillation progression phenotypes using Troponin T. Int. J. Cardiol. 2019, 297, 61–65. [Google Scholar] [CrossRef]
- Paris, S.; Inciardi, R.M.; Lombardi, C.M.; Tomasoni, D.; Ameri, P.; Carubelli, V.; Agostoni, P.; Canale, C.; Carugo, S.; Danzi, G.; et al. Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: Results of the Cardio-COVID-Italy multicentre study. Europace 2021, 23, 1603–1611. [Google Scholar] [CrossRef] [PubMed]
- Miyazawa, K.; Pastori, D.; Lip, G.Y.H. Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants. Am. Heart J. 2018, 198, 166–168. [Google Scholar] [CrossRef] [PubMed]
- Alonso, A.; Lopez, F.L.; Matsushita, K.; Loehr, L.R.; Agarwal, S.K.; Chen, L.Y.; Soliman, E.Z.; Astor, B.C.; Coresh, J. Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011, 123, 2946–2953. [Google Scholar] [CrossRef] [PubMed]
- Watanabe, H.; Watanabe, T.; Sasaki, S.; Nagai, K.; Roden, D.M.; Aizawa, Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. Am. Heart J. 2009, 158, 629–636. [Google Scholar] [CrossRef] [PubMed]
Cases (N = 115) | Controls (N = 33) | p | |
---|---|---|---|
Age | 63 ± 9 | 62 ± 10 | 0.464 |
Men | 82 (71.30%) | 17 (51.51%) | 0.033 |
Hypertension | 65 (56.52%) | 15 (45.45%) | 0.261 |
Diabetes | 15 (13.04%) | 4 (12.12%) | 0.889 |
COPD | 5 (4.34%) | 1 (3.03%) | 0.729 |
Smoking | 19 (16.52%) | 8 (24.24%) | 0.322 |
CRD | 2 (1.739%) | 1 (3.03%) | 0.643 |
Stroke | 3 (2.60%) | 1 (3.03%) | 0.895 |
Previous myocardial infarction | 6 (5.21%) | 1 (3.03%) | 0.602 |
OSAHS | 10 (8.69%) | 2 (6.06%) | 0.625 |
Cases (N = 115) | Controls (N = 33) | p | |
---|---|---|---|
NT-proBNP (pg/mL) | 1054.20 ± 833.30 | 58.31 ± 59.40 | <0.001 |
Galectin-3 (ng/mL) | 16.87 ± 4.89 | 22.71 ± 21.94 | 0.139 |
ST2 (ng/mL) | 35.43 ± 15.89 | 27.43 ± 10.95 | <0.001 |
Fibrinogen (mg/dl) | 329.40 ± 75.87 | 315.33 ± 73.31 | 0.346 |
Hs-Tn T (ng/L) | 10.25 ± 6.11 | 8.42 ± 6.85 | <0.001 |
Urate (mg/dl) | 6.11 ± 1.45 | 6.38 ± 7.68 | 0.845 |
CRP (mg/L) | 5.06 ± 14.8 | 2.46 ± 2.10 | 0.326 |
Hemoglobin (g/dl) | 14.97 ± 1.43 | 14.56 ± 1.29 | 0.150 |
Creatinine (mg/dl) | 0.95 ± 0.19 | 0.79 ± 0.12 | <0.001 |
Glomerular filtration (mL/min) | 79.45 ± 15.23 | 90.54 ± 10.07 | <0.001 |
Odds Ratio | 95% Confidence Interval | p | |
---|---|---|---|
NT-proBNP (pg/mL) | 1.03 | 1.01–1.04 | <0.001 |
ST2 (ng/mL) | 1.25 | 0.88–1.79 | 0.215 |
Hs-Tn T (ng/L) | 0.81 | 0.61–1.08 | 0.159 |
Men | 37.60 | 0.51–2770.86 | 0.098 |
Glomerular filtration (mL/min) | 0.93 | 0.82–1.04 | 0.220 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Merino-Merino, A.; Saez-Maleta, R.; Salgado-Aranda, R.; AlKassam-Martinez, D.; Pascual-Tejerina, V.; Martin-Gonzalez, J.; Garcia-Fernandez, J.; Perez-Rivera, J.-A. A Differential Profile of Biomarkers between Patients with Atrial Fibrillation and Healthy Controls. J. Pers. Med. 2022, 12, 1406. https://doi.org/10.3390/jpm12091406
Merino-Merino A, Saez-Maleta R, Salgado-Aranda R, AlKassam-Martinez D, Pascual-Tejerina V, Martin-Gonzalez J, Garcia-Fernandez J, Perez-Rivera J-A. A Differential Profile of Biomarkers between Patients with Atrial Fibrillation and Healthy Controls. Journal of Personalized Medicine. 2022; 12(9):1406. https://doi.org/10.3390/jpm12091406
Chicago/Turabian StyleMerino-Merino, Ana, Ruth Saez-Maleta, Ricardo Salgado-Aranda, Daniel AlKassam-Martinez, Virginia Pascual-Tejerina, Javier Martin-Gonzalez, Javier Garcia-Fernandez, and Jose-Angel Perez-Rivera. 2022. "A Differential Profile of Biomarkers between Patients with Atrial Fibrillation and Healthy Controls" Journal of Personalized Medicine 12, no. 9: 1406. https://doi.org/10.3390/jpm12091406